Clinical Trials

Muscle Invasive Bladder Urothelial Carcinoma

NCT07061964 2026-04-22

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

111 enrolled

Urinary Bladder Neoplasms

NCT04981509 2026-04-21

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

65 enrolled

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT06378866 2026-04-20

DIVINE

532 enrolled

Prostatic Neoplasms

NCT07219147 2026-04-20

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

NCT04071236 2026-04-17

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Phase 1/2 Recruiting

90 enrolled

Lymphatic Metastasis, Prostatic Neoplasms

NCT04628767 2026-04-17

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2/3 Recruiting

249 enrolled

Renal Pelvis and Ureter Urothelial Carcinoma

NCT07218913 2026-04-17

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

44 enrolled

Testicular Neoplasms, Seminoma, Hearing Loss

NCT06524544 2026-04-15

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

320 enrolled

Carcinoma, Transitional Cell

NCT06770582 2026-04-15

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

160 enrolled

Urinary Bladder Neoplasms

NCT04550494 2026-04-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

BreastGastrointestinalGenitourinaryGynecologic

36 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT05691465 2026-04-13

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Prostatic Neoplasms

NCT06439836 2026-04-13

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

27 enrolled

Carcinoma, Transitional Cell

NCT05327686 2026-04-08

SAMURAI

240 enrolled

Carcinoma, Renal Cell

NCT07097142 2026-04-08

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

486 enrolled

Urinary Bladder Neoplasms

NCT06632977 2026-04-07

PREDICT

474 enrolled

Prostatic Neoplasms

NCT06931340 2026-04-07

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

1,260 enrolled

Prostatic Neoplasms

NCT07000084 2026-04-07

GAIN-BCG

330 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06389786 2026-04-06

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

Phase NA Recruiting

50 enrolled

Prostatic Neoplasms

NCT04423211 2026-04-03

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

804 enrolled

Prostatic Neoplasms

NCT05946213 2026-04-03

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

1,209 enrolled

Prostatic Neoplasms

NCT06500455 2026-04-03

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

BreastCNSDermatologicGenitourinaryThoracic

269 enrolled

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT06325046 2026-03-31

Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer

Phase NA Recruiting

144 enrolled

Prostatic Neoplasms

NCT06526299 2026-03-24

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

51 enrolled

Prostatic Neoplasms

NCT07145177 2026-03-23

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

Prostatic Neoplasms

NCT05888532 2026-03-17

64Cu-GRIP B in Patients With Advanced Malignancies

Phase 1/2 Recruiting

91 enrolled

Kidney Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Lipodystrophy, Congenital Generalized

NCT06288113 2026-03-13

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

40 enrolled

Prostatic Neoplasms

NCT07025369 2026-03-13

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial